Lineage Cell Therapeutics, Inc.
LCTX
$0.5111
$0.02555.25%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 19.42% | 6.19% | -0.60% | -41.22% | -32.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.42% | 6.19% | -0.60% | -41.22% | -32.48% |
| Cost of Revenue | -15.68% | -22.68% | 7.56% | 61.42% | 209.64% |
| Gross Profit | 55.61% | 57.44% | -27.77% | -512.21% | -200.53% |
| SG&A Expenses | 28.38% | 31.94% | -16.32% | -20.20% | -25.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.66% | 2.75% | -17.36% | -17.10% | -15.58% |
| Operating Income | -0.47% | -1.30% | 23.23% | 6.33% | 6.78% |
| Income Before Tax | 31.59% | 20.19% | 19.59% | -3.67% | 5.19% |
| Income Tax Expenses | -- | -- | 100.00% | 100.00% | 100.00% |
| Earnings from Continuing Operations | 31.59% | 13.49% | 13.32% | -9.59% | 0.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -69.57% | -285.71% | -204.84% | -73.77% | -121.70% |
| Net Income | 31.49% | 13.39% | 12.81% | -9.82% | -0.42% |
| EBIT | -0.47% | -1.30% | 23.23% | 6.33% | 6.78% |
| EBITDA | -0.96% | -1.75% | 23.66% | 6.35% | 6.89% |
| EPS Basic | 41.64% | 22.83% | 18.44% | -3.71% | 2.96% |
| Normalized Basic EPS | 30.55% | 17.58% | 37.50% | 15.38% | 19.20% |
| EPS Diluted | 41.64% | 22.83% | 18.44% | -3.71% | 3.10% |
| Normalized Diluted EPS | 30.55% | 17.58% | 37.50% | 15.38% | 19.20% |
| Average Basic Shares Outstanding | 19.98% | 15.95% | 7.29% | 6.04% | 3.49% |
| Average Diluted Shares Outstanding | 19.98% | 15.95% | 7.29% | 6.04% | 3.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |